Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
MIAMI, May 12, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq:ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2023.
Related news for (ATXI)
- Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
- Sidoti Events, LLC’s Virtual January Micro-Cap Conference
- Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
- Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
- Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol